Patents by Inventor Benjamin Ebert
Benjamin Ebert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230151342Abstract: The disclosure includes compositions comprising synthetic zinc finger degrons, and their use with non-naturally occurring or engineered programmable nucleases. Compositions specifically targeting the engineered programmable nucleases for control of gene editing outcomes, and compositions, systems and method of use are further detailed.Type: ApplicationFiled: February 26, 2021Publication date: May 18, 2023Inventors: Amit CHOUDHARY, Donghyun LIM, Sreekanth VEDAGOPURAM, Benjamin EBERT, Max JAN
-
Publication number: 20220362228Abstract: The present invention features methods for increasing sensitivity and/or reversing resistance to chemotherapy, methods for treating or preventing a cancer in a subject, methods for treating clonal hematopoiesis of indeterminate potential in a subject, and methods of identifying resistance or sensitivity to chemotherapy in a subject. In some embodiments, the methods contain the step of administering an agent that inhibits the expression or activity of a Protein phosphatase 1D (PPM1D) polypeptide or polynucleotide. The present invention also features compositions for increasing sensitivity and/or reversing resistance to chemotherapy.Type: ApplicationFiled: March 7, 2022Publication date: November 17, 2022Applicant: The Brigham And Women's Hospital, Inc.Inventors: Josephine KAHN, Siddhartha JAISWAL, Benjamin EBERT
-
Publication number: 20220281931Abstract: The invention features methods for characterizing a cancer as sensitive or resistant to Bcl6 therapies, as well as compositions and methods for inducing the degradation or polymerization of a polypeptide of interest.Type: ApplicationFiled: May 20, 2022Publication date: September 8, 2022Applicants: Dana-Farber Cancer Institute, Inc., Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Benjamin EBERT, Mikolaj SLABICKI, Eric S. FISCHER, Hojong YOON, Jonas KOEPPEL
-
Patent number: 11426405Abstract: The methods described herein include methods for the treatment of subjects who have Clonal Hematopoiesis of Indeterminate Potential (CHIP) or a Philadelphia-negative myeloproliferative neoplasm (MPN), e.g., polycythaemia vera (PV) or essential thrombocythaemia (ET), using inhibitors of JAK-STAT signaling.Type: GrantFiled: December 4, 2018Date of Patent: August 30, 2022Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center CorporationInventors: Rob Sellar, Benjamin Ebert, Ofir Wolach, Kimberly Martinod, Denisa Wagner
-
Patent number: 11304938Abstract: The present invention features methods for increasing sensitivity and/or reversing resistance to chemotherapy, methods for treating or preventing a cancer in a subject, methods for treating clonal hematopoiesis of indeterminate potential in a subject, and methods of identifying resistance or sensitivity to chemotherapy in a subject. In some embodiments, the methods contain the step of administering an agent that inhibits the expression or activity of a Protein phosphatase 1D (PPM1D) polypeptide or polynucleotide. The present invention also features compositions for increasing sensitivity and/or reversing resistance to chemotherapy.Type: GrantFiled: March 10, 2017Date of Patent: April 19, 2022Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Josephine Kahn, Siddhartha Jaiswal, Benjamin Ebert
-
Patent number: 11015223Abstract: Disclosed are methods for predicting a response of a subject with myelodysplastic syndrome to treatment with a hypomethylating agent, for example using a sample obtained from the subject. The methods can be used to select a subject for treatment with a hypomethylating agent, and/or measure a subject's response to therapy and/or disease progression/regression. The methods include detecting, in a nucleic acid sample obtained from a subject, one or more mutations of any one or more genes selected from Table 3a.Type: GrantFiled: May 12, 2014Date of Patent: May 25, 2021Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAT . INCInventors: Rafael Bejar, Benjamin Ebert, Donna Neuberg, Kristen Stevenson
-
Publication number: 20210137902Abstract: The present invention features methods for increasing sensitivity and/or reversing resistance to chemotherapy, methods for treating or preventing a cancer in a subject, methods for treating clonal hematopoiesis of indeterminate potential in a subject, and methods of identifying resistance or sensitivity to chemotherapy in a subject. In some embodiments, the methods contain the step of administering an agent that inhibits the expression or activity of a Protein phosphatase 1D (PPM1D) polypeptide or polynucleotide. The present invention also features compositions for increasing sensitivity and/or reversing resistance to chemotherapy.Type: ApplicationFiled: March 10, 2017Publication date: May 13, 2021Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: JOSEPHINE KAHN, SIDDHARTHA JAISWAL, BENJAMIN EBERT
-
Publication number: 20210040166Abstract: The present disclosure relates to therapeutic methods and clinically useful molecular switches, for which activity or degradation of a switch-presenting polypeptide can be precisely induced via administration or withdrawal of an FDA-approved drug. Certain aspects of the disclosure relate to an engineered drug-inducible heterodimeric system including a first polypeptide presenting a CRBN polypeptide disrupted for or lacking a DDB1-interacting domain and a second polypeptide presenting a CRBN polypeptide substrate, where binding between the CRBN polypeptide and the CRBN polypeptide substrate are inducible via administration of an FDA-approved thalidomide analog immunomodulatory drug (IMiD). Another aspect of the disclosure relates to a chimeric antigen receptor (CAR) that presents a minimal fragment of the CRBN polypeptide substrate IKZF3 capable of triggering proteasomal degradation of CAR upon administration of an FDA-approved IMiD.Type: ApplicationFiled: October 30, 2018Publication date: February 11, 2021Applicants: THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM & WOMEN'S HOSPITAL, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Max Jan, Quinlan L. Sievers, Benjamin Ebert, Marcela Maus
-
Publication number: 20200131576Abstract: The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1? inhibitor, wherein the subject has a TET2 and/or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and/or DNMT3A, if it is determined that the subject has at least one TET2 and/or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1? inhibitor to a subject to the subject thereby treating atherosclerosis.Type: ApplicationFiled: April 24, 2018Publication date: April 30, 2020Applicants: The Brigham and Women's Hospital, Inc., The General Hospital CorporationInventors: Jaiswal Siddhartha, Sekar Kathiresan, Benjamin Ebert
-
Publication number: 20190167680Abstract: The methods described herein include methods for the treatment of subjects who have Clonal Hematopoiesis of Indeterminate Potential (CHIP) or a Philadelphia-negative myeloproliferative neoplasm (MPN), e.g., polycythaemia vera (PV) or essential thrombocythaemia (ET), using inhibitors of JAK-STAT signaling.Type: ApplicationFiled: December 4, 2018Publication date: June 6, 2019Inventors: Rob Sellar, Benjamin Ebert, Ofir Wolach, Kim Martinod, Denisa Wagner
-
Publication number: 20160083802Abstract: Disclosed are methods for predicting a response of a subject with myelodysplastic syndrome to treatment with a hypomethylating agent, for example using a sample obtained from the subject. The methods can be used to select a subject for treatment with a hypomethylating agent, and/or measure a subject's response to therapy and/or disease progression/regression. The methods include detecting, in a nucleic acid sample obtained from a subject, one or more mutations of any one or more genes selected from Table 3a.Type: ApplicationFiled: May 12, 2014Publication date: March 24, 2016Inventors: Rafael BEJAR, Benjamin EBERT, Donna NEUBERG, Kristen STEVENSON
-
Patent number: 9164094Abstract: The invention relates to expression profiles of HIV-specific T-cells and their methods of use, including but not limited to treatment of HIV, increasing T-cell function and/or survival in HIV infected subjects, monitoring HIV disease progression and classifying HIV infected subjects as controllers or chronic progressors.Type: GrantFiled: April 20, 2012Date of Patent: October 20, 2015Assignees: Dana-Farber Cancer Institute, Brigham and Women's Hospital, The General Hospital CorporationInventors: W. Nicholas Haining, Benjamin Ebert, Bruce Walker
-
Patent number: 8828965Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: GrantFiled: August 21, 2013Date of Patent: September 9, 2014Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Massachusetts Institute of TechnologyInventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Publication number: 20140050707Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: ApplicationFiled: August 21, 2013Publication date: February 20, 2014Applicants: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Patent number: 8530443Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: GrantFiled: October 16, 2012Date of Patent: September 10, 2013Assignees: The General Hospital Corporation, Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.Inventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Publication number: 20130039895Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: ApplicationFiled: October 16, 2012Publication date: February 14, 2013Applicants: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Publication number: 20130005792Abstract: The invention relates to expression profiles of HIV-specific T-cells and their methods of use, including but not limited to treatment of HIV, increasing T-cell function and/or survival in HIV infected subjects, monitoring HIV disease progression and classifying HIV infected subjects as controllers or chronic progressors.Type: ApplicationFiled: April 20, 2012Publication date: January 3, 2013Applicants: Dana-Farber Cancer Institute, The General Hospital Corporation, Brigham & Women's HospitalInventors: W. N. Haining, Benjamin Ebert, Bruce Walker
-
Publication number: 20090202493Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: ApplicationFiled: January 30, 2009Publication date: August 13, 2009Applicants: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub